Drug Profile
GSK 2292767
Alternative Names: GSK2292767Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Indazoles; Morpholines; Oxazoles; Small molecules; Sulfonamides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 30 Oct 2019 Discontinued - Phase-I for Asthma (In volunteers) in United Kingdom (Inhalation) (GlaxoSmithKline pipeline, October 2019)
- 01 Feb 2017 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (Inhalation) (NCT03045887)
- 01 Aug 2015 Preclinical trials in Asthma in United Kingdom (Inhalation)